{"news_desk": "Business", "print_page": "1", "subsection_name": "International Business", "section_name": "Business Day", "byline": {"original": "By DAVID BARBOZA", "person": [{"firstname": "David", "rank": 1, "lastname": "BARBOZA", "organization": "", "role": "reported"}]}, "abstract": "Chinese government's harsh legal crackdown on misconduct by GlaxoSmithKline, which included fraud and bribery, reflects country's increasingly assertive approach to multinational companies on its soil; case of Peter Humphrey, who was arrested in China while working as corporate investigator for pharmaceutical company, cited (Series: China Rules).", "type_of_material": "News", "word_count": "3473", "keywords": [{"rank": "1", "value": "China", "is_major": "Y", "name": "glocations"}, {"rank": "12", "value": "Series", "is_major": "Y", "name": "subject"}, {"rank": "2", "value": "GlaxoSmithKline PLC", "is_major": "Y", "name": "organizations"}, {"rank": "3", "value": "Bribery and Kickbacks", "is_major": "Y", "name": "subject"}, {"rank": "4", "value": "Frauds and Swindling", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "Whistle-Blowers", "is_major": "N", "name": "subject"}, {"rank": "6", "value": "Fines (Penalties)", "is_major": "N", "name": "subject"}, {"rank": "7", "value": "Humphrey, Peter", "is_major": "Y", "name": "persons"}, {"rank": "8", "value": "Reilly, Mark", "is_major": "N", "name": "persons"}, {"rank": "9", "value": "Shi, Vivian", "is_major": "N", "name": "persons"}, {"rank": "10", "value": "ChinaWhys", "is_major": "N", "name": "organizations"}], "lead_paragraph": "China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties.", "pub_date": "2016-11-01T22:59:47Z", "document_type": "article", "source": "The New York Times", "snippet": "China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbWide.jpg"}, {"height": 479, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "479", "xlarge": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/11/02/business/international/china-rules-glaxo-bribes-sex-tape-whistleblower-cautionary-tale.html", "slideshow_credits": null, "blog": [], "_id": "58191e6d7c459f606398d030", "headline": {"main": "Drug Giant Faced a Reckoning as China Took Aim at Bribery", "content_kicker": "China Rules", "print_headline": "China Tightens Its Grip, and Glaxo Pays a Price", "kicker": "China Rules"}}